肺低级别神经内分泌肿瘤的系统治疗  

Systemic Therapy for Low-grade Pulmonary Neuroendocrine Tumor

作　　者：王峥[1] 程世钊[1] 周方[1] 韩兴鹏[1] 卢喜科[1] 孙大强[1] 张逊[1] Zheng WANG;Shizhao CHENG;Fang ZHOU;Xingpeng HAN;Xike LU;Daqiang SUN;Xun ZHANG(Department of Thoracic Surgery,Tianjin Chest Hospital,Tianjin 300000,China)

机构地区：[1]天津市胸科医院胸外科,天津300000

出　　处：《中国肺癌杂志》2019年第1期34-39,共6页Chinese Journal of Lung Cancer

摘　　要：肺部是神经内分泌肿瘤(neuroendocrine tumor, NET)的第二好发部位。肺类癌包括典型类癌和不典型类癌,属于低级别神经内分泌肿瘤。这一类肿瘤由于发病率较低,目前尚未得到广大医务工作者的重视。但有效的治疗不仅能提高患者的远期生存,还能控制患者症状,改善生活质量。本文分别阐述肺低级别神经内分泌肿瘤的流行病学和病理学特点、早期患者的治疗策略以及进展期患者的治疗策略。早期患者应当尽早进行手术治疗。进展期患者治疗方式包括化疗、SSAs、mTOR抑制剂、肽受体介导的放射性核素治疗、生物治疗以及靶向治疗。目前的研究结论大多来自其他部位的NETs研究外推而来,仍需针对肺低级别神经内分泌肿瘤患者进行特异性临床试验加以证实。The lung is the second most common site of neuroendocrine tumors(NETs). Typical and atypical carcinoids are low-grade NETs of the lung. These rare tumors have received little attention and education is needed for treating physicians. The article describes the classifcation of lung NETs, the epidemiology and pathological characteristics. When lung NETs are diagnosed at an early stage, surgical intervention is often curative. For advanced lung NETs patients, different treatment methods including chemotherapy, somatostatin analogs, m-TOR inhibition, peptide receptor radioligand therapy, and biologic systemic therapy are discussed. The conclusions are generally extrapolated from the outcome of extra-pulmonary carcinoids. Prospective randomized well-designed trials are urgently needed to inform current recommendations on systemic treatment.

关 键 词：神经内分泌肿瘤 肺 治疗 

分 类 号：R734.2[医药卫生—肿瘤]